Articles

Cellular stress can lead to misfolded proteins

Duke University study reveals that cells can slow their processes to deal with misshapen proteins, which are implicated in diseases such as type 2 diabetes and Alzheimer’s disease
Written byKelsey Kaustinen
| 2 min read

DURHAM, N.C.—A team of researchers at Duke University in North Carolina and Singapore has discovered that stress on cells can lead to the production of proteins that are unfolded or misfolded, which in turn can lead to a number of different diseases. To combat this, cells are capable of adjusting the process of producing proteins.

Christopher V. Nicchitta, Ph.D., a professor of cell biology at Duke University School of Medicine, presented it as such: “Essentially, the cell remodels the organization of its protein production machinery in order to compartmentalize the tasks at hand.”

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of a single cell surrounded by small molecular particles in a red biological environment.
Measuring mRNA and protein together at single cell resolution can uncover tumor-specific signaling activity and immune features.
Illustration of an antibody intertwined with a DNA double helix.
Discover how CRISPR and single-cell RNA sequencing can connect disease-associated variants to regulatory elements, genes, and pathways.
Digital illustration of the human digestive system highlighting the liver, stomach, and intestines.
Explore how human gut-liver models can improve the translation of preclinical findings into clinical pharmacokinetic predictions.